Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

September 14, 2016September 14, 2016

Supportive Data on Seizure Medications, Fycompa and Banzel/Inovelon, Presented at ECE 2016

News

Several abstracts from Eisai on its epilepsy treatments Fycompa (perampanel) and rufinamide (marketed as Inovelon in Europe and Banzel in the U.S.) were recently presented at this year’s 12th European Congress on Epileptology (ECE). The data provided ... Read more

August 26, 2016

Most People with Epilepsy Experience Headaches, Study Shows

News

The majority of people with epilepsy experience headaches regardless of gender or age, according to research from Vilnius University, in Lithuania. The study, titled “The burden of headache in people with epilepsy,” ... Read more

August 12, 2016

Anti-seizure Therapies for Epilepsy Patients May Induce Psychotic Disorders, Study Finds

News

A new study indicates that antiepileptic drugs designed to reduce seizures may also induce psychotic disorders in some patients with epilepsy. The study, “Psychotic disorders induced by antiepileptic drugs in people ... Read more

June 29, 2016

Data for ZYN002 CBD Gel Phase 1 Trial in Epilepsy, other Disease Released by Zynerba

News

Zynerba Pharmaceuticals, Inc. recently reported positive top line data from its Phase 1 ascending dose study of ZYN002, the first non-psychoactive cannabinoid, formulated as a gel for transdermal delivery for patients ... Read more

June 21, 2016January 24, 2017

New Clinical Trial for Epilepsy to Begin Testing Visualase Surgical System

News

The U.S. Food and Drug Administration (FDA) has approved a clinical trial for Medtronic’s Visualase laser-ablation system for people with drug-resistant mesial temporal lobe epilepsy (MTLE), a condition marked by seizures not treated effectively with antiseizure ... Read more

June 15, 2016

Ganaxolone, for Adult Focal Onset Seizures, Fails to Meet Primary Endpoint in Phase 3 Study, Marinus Announces

News

Marinus Pharmaceuticals recently reported that their drug candidate ganaxolone, developed for adults with drug-resistant focal onset epilepsy, did not meet the primary endpoint in a Phase 3 clinical trial. The trial demonstrated no ... Read more